Google
Trusted Resources: News & Events
Latest announcements and gatherings
New Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial Shows
A new pre-transplant conditioning regimen remarkably improves rejection rates and survival in children with sickle cell disease (SCD), according to the results of Phase 1/2 trial (NCT00920972).
The study, “Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced Intensity Conditioning: Results of a Phase I Trial,” appeared in the journal Biology of Blood and Marrow Transplantation.
Transplanting hematopoietic stem cells (cells that can develop into any type of blood cell) from matched sibling donors results in disease-free survival of greater than 90% in SCD patients. However, only about 18% of patients have suitable sibling donors.
Therefore, unrelated umbilical cord blood transplant (UCBT), which has been performed to treat diseases such as inherited metabolic disorders and primary immunodeficiency, became a viable alternative for patients with severe sickle cell disease and without a matched family donor.
+myBinderRelated Content
-
Magnesium for treating sickle cell diseaseBACKGROUND: Sickle cell disease is an a...
-
HHS Secretary Alex Azar Touts White House Efforts to Fight Sickle Cell DiseaseBy 2029, Americans with sickle cell dise...
-
Treatments for priapism in boys and men with sickle cell diseaseBACKGROUND: Sickle cell disease compris...
-
FDA grants CRISPR gene therapy fast track designation for sickle cell diseaseThe FDA granted fast track designation t...
-
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
-
Statement from FDA Commissioner on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are...
-
Sickle cell warrior documentaryhttps://www.youtube.com/watch?v=ZxC4vtN2...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.